COVENANT THERAPEUTICS, LLC

Biotech · Private

Short peptide erythropoietin analog optimized for weekly dosing to treat anemia

Grants
$698K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Drug Discovery for Idiopathic Pulmonary Fibrosis$224,669
Federal grantDepartment of Health and Human Services · Phase I · Novel Class Therapy for IPF$223,276
Federal grantDepartment of Health and Human Services · Phase I · Designing safe, potent, and cost-effective small peptide erythropoietin analogs$249,965
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1347Flare Therapeutics——
1348NEURO10-9 PHARMA INC——
1349OXT THERAPEUTICS, INC.——
1350COVENANT THERAPEUTICS, LLC——
1351ADVAC, LLC——
1352CALEO BIOTECHNOLOGIES, INC.——
1353SOLVEXA, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.